𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study

✍ Scribed by David J. Stewart; Robert M. O'Bryan; Muhyi Al-Sarraf; John J. Costanzi; Noboru Oishi

Publisher
Springer US
Year
1983
Tongue
English
Weight
215 KB
Volume
1
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

✦ Synopsis

Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m 2 I.V. daily for three days every 3 4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced complete remissions and two additional patients experienced partial remissions. Three patients stabilized. Gastrointestinal toxicity was generally mild. Further studies are planned of Cisplatin in combination with other agents.

πŸ“œ SIMILAR VOLUMES

Cisplatin in recurrent pediatric brain t
Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
✍ Charles L. Sexauer; Atiya Khan; Peter C. Burger; Jeffrey P. Krischer; Jan Van Ey πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m\*/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) sca

A phase II evaluation of cisplatin in un
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
✍ Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 240 KB

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea

Phase II evaluation of bleomycin. A Sout
Phase II evaluation of bleomycin. A Southwest Oncology Group study
✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 369 KB πŸ‘ 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

Phase II study of weekly intravenous men
Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults
✍ David J. Stewart; Herman Hugenholtz; Vasco F. DaSilva; Brian G. Benoit; Michael πŸ“‚ Article πŸ“… 1992 πŸ› Springer US 🌐 English βš– 435 KB

Twenty patients with astrocytomas recurrent after surgery + radiation were treated on a phase II protocol of the new anthracycline derivative menogaril 115 mg/m 2 administered intravenously once per week. Sixteen patients were evaluable for treatment efficacy. No patient achieved a major therapeutic

Phase II trial of carboplatin and paclit
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study
✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local